Advertisement
New Zealand markets close in 38 minutes

  • NZX 50

    12,612.75
    +25.77 (+0.20%)
     

  • NZD/USD

    0.6216
    +0.0006 (+0.10%)
     

  • NZD/EUR

    0.5587
    +0.0006 (+0.10%)
     

  • ALL ORDS

    8,399.90
    +35.60 (+0.43%)
     

  • ASX 200

    8,174.60
    +32.50 (+0.40%)
     

  • OIL

    70.81
    -0.10 (-0.14%)
     

  • GOLD

    2,587.60
    -11.00 (-0.42%)
     

  • NASDAQ

    19,344.49
    -87.90 (-0.45%)
     

  • FTSE

    8,253.68
    -56.18 (-0.68%)
     

  • Dow Jones

    41,503.10
    -103.08 (-0.25%)
     

  • DAX

    18,711.49
    -14.59 (-0.08%)
     

  • Hang Seng

    17,978.83
    +318.81 (+1.81%)
     

  • NIKKEI 225

    37,285.63
    +905.46 (+2.49%)
     

  • NZD/JPY

    89.0010
    +0.7930 (+0.90%)
     

Revvity Second Quarter 2024 Earnings: EPS Misses Expectations

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

Revvity (NYSE:RVTY) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$691.7m (down 2.5% from 2Q 2023).

  • Net income: US$72.6m (up 24% from 2Q 2023).

  • Profit margin: 11% (up from 8.3% in 2Q 2023).

  • EPS: US$0.59 (up from US$0.47 in 2Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revvity EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 10.0%.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are up 16% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Revvity that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com